Related Experiment Video
Updated: Feb 25, 2026
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
The Mechanism of Action of LCZ696
1Department of Pharmacology, School of Medicine, University Complutense, Madrid, Spain.
Insights
New drug LCZ696 (sacubitril/valsartan) effectively treats heart failure (HF) by targeting both the renin-angiotensin aldosterone system (RAAS) and natriuretic peptide pathways, showing superiority over enalapril in key patient groups.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Engineering
Background:
- Heart failure (HF) poses a significant and increasing financial burden on global healthcare systems.
- Despite therapeutic advancements, HF continues to have high mortality rates.
- Current HF treatments primarily target neurohormonal pathways like the renin-angiotensin aldosterone system (RAAS).
Purpose of the Study:
- To evaluate the efficacy and safety of LCZ696 (sacubitril/valsartan), a novel dual-acting drug, in managing heart failure.
- To investigate the unique mechanism of action of LCZ696, which inhibits both the RAAS and neprilysin.
- To compare the effectiveness of LCZ696 against established treatments like enalapril in HF patients.
Main Methods:
- LCZ696 is a first-in-class angiotensin II AT[1] receptor neprilysin inhibitor.
- Clinical studies assessed LCZ696's performance in patients with arterial hypertension and various stages of HF.
- Comparative analysis was performed against enalapril in patients with moderate to severe HF and reduced left ventricular ejection fraction.
Main Results:
- LCZ696 demonstrated efficacy and safety in patients with mild to moderate arterial hypertension.
- The drug proved effective and safe in HF patients with preserved ejection fraction.
- LCZ696 showed superiority compared to enalapril in patients with moderate to severe HF and reduced left ventricular ejection fraction.
Conclusions:
- LCZ696 offers a novel therapeutic approach for heart failure by simultaneously targeting beneficial natriuretic peptide pathways and detrimental RAAS activation.
- The drug is effective and safe across a spectrum of cardiovascular conditions, including hypertension and HF with preserved and reduced ejection fraction.
- LCZ696 represents a significant advancement in HF treatment, outperforming enalapril in specific patient populations.
Abstract:
Heart failure (HF) represents a growing financial burden on healthcare systems and despite therapeutic advances, mortality remains high. Current treatments focus on blocking neurohormonal pathways, such as the renin-angiotensin aldosterone system (RAAS). Recent research has focused on the natriuretic peptide system, which confers beneficial effects in HF, whereas activation of the RAAS and of the sympathetic nervous system has detrimental effects. LCZ696 (sacubutril/valsartan), a first-in-class angiotensin II AT[1] receptor neprilysin inhibitor, has a unique mode of action that targets both pathways. Clinical studies to date indicate that LCZ696 is effective and safe in mild to moderate arterial hypertension and in HF patients with preserved ejection fraction, and has been shown to be superior to enalapril in patients with moderate to severe HF due to reduced left ventricular ejection fraction.
More Related Videos
09:09Author Spotlight: Regulation and Dysregulation of ER-Mitochondria Contacts — Implications for Neurodegenerative Disease Pathogenesis
Published on: October 11, 2024
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Related Concept Videos
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
01:28Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
01:28Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...